Arnaud, MarionDuchamp, MargauxBobisse, SaraRenaud, PhilippeCoukos, GeorgeHarari, Alexandre2020-02-072020-02-072020-01-0810.1016/j.copbio.2019.12.014https://infoscience.epfl.ch/handle/20.500.14299/165201Among immune correlates of clinical responses, tumor-specificneoantigens took the spotlight as relevant targets for cancerimmunotherapy. The implementation of pipelines forpersonalized cancer therapy remains challenging due to theprivacy, that is patient-specificity, of neoantigens and the low-frequency of neoantigen-specific T cells in blood and tumorsamples. To overcome these obstacles, recent developmentsin the field of biotechnology have allowed the multiplexedidentification of neoepitope-specific T cells. This reviewaddresses the pros and cons of conventional neoantigenscreening methodologies and highlights the current as well asthe prospective biotechnological opportunities in the field.text::journal::journal article::research article